Cargando…

Evaluating the performance of copula models in phase I-II clinical trials under model misspecification

BACKGROUND: Traditionally, phase I oncology trials are designed to determine the maximum tolerated dose (MTD), defined as the highest dose with an acceptable probability of dose limiting toxicities(DLT), of a new treatment via a dose escalation study. An alternate approach is to jointly model toxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunanan, Kristen, Koopmeiners, Joseph S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234400/
https://www.ncbi.nlm.nih.gov/pubmed/24731155
http://dx.doi.org/10.1186/1471-2288-14-51
_version_ 1782344851765854208
author Cunanan, Kristen
Koopmeiners, Joseph S
author_facet Cunanan, Kristen
Koopmeiners, Joseph S
author_sort Cunanan, Kristen
collection PubMed
description BACKGROUND: Traditionally, phase I oncology trials are designed to determine the maximum tolerated dose (MTD), defined as the highest dose with an acceptable probability of dose limiting toxicities(DLT), of a new treatment via a dose escalation study. An alternate approach is to jointly model toxicity and efficacy and allow dose escalation to depend on a pre-specified efficacy/toxicity tradeoff in a phase I-II design. Several phase I-II trial designs have been discussed in the literature; while these model-based designs are attractive in their performance, they are potentially vulnerable to model misspecification. METHODS: Phase I-II designs often rely on copula models to specify the joint distribution of toxicity and efficacy, which include an additional correlation parameter that can be difficult to estimate. We compare and contrast three models for the joint probability of toxicity and efficacy, including two copula models that have been proposed for use in phase I-II clinical trials and a simple model that assumes the two outcomes are independent. We evaluate the performance of the various models through simulation both when the models are correct and under model misspecification. RESULTS: Both models exhibited similar performance, as measured by the probability of correctly identifying the optimal dose and the number of subjects treated at the optimal dose, regardless of whether the data were generated from the correct or incorrect copula, even when there is substantial correlation between the two outcomes. Similar results were observed for a simple model that assumes independence, even in the presence of strong correlation. Further simulation results indicate that estimating the correlation parameter in copula models is difficult with the sample sizes used in Phase I-II clinical trials. CONCLUSIONS: Our simulation results indicate that the operating characteristics of phase I-II clinical trials are robust to misspecification of the copula model but that a simple model that assumes independence performs just as well due to difficulty in estimating the copula model correlation parameters from binary data.
format Online
Article
Text
id pubmed-4234400
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42344002014-11-19 Evaluating the performance of copula models in phase I-II clinical trials under model misspecification Cunanan, Kristen Koopmeiners, Joseph S BMC Med Res Methodol Research Article BACKGROUND: Traditionally, phase I oncology trials are designed to determine the maximum tolerated dose (MTD), defined as the highest dose with an acceptable probability of dose limiting toxicities(DLT), of a new treatment via a dose escalation study. An alternate approach is to jointly model toxicity and efficacy and allow dose escalation to depend on a pre-specified efficacy/toxicity tradeoff in a phase I-II design. Several phase I-II trial designs have been discussed in the literature; while these model-based designs are attractive in their performance, they are potentially vulnerable to model misspecification. METHODS: Phase I-II designs often rely on copula models to specify the joint distribution of toxicity and efficacy, which include an additional correlation parameter that can be difficult to estimate. We compare and contrast three models for the joint probability of toxicity and efficacy, including two copula models that have been proposed for use in phase I-II clinical trials and a simple model that assumes the two outcomes are independent. We evaluate the performance of the various models through simulation both when the models are correct and under model misspecification. RESULTS: Both models exhibited similar performance, as measured by the probability of correctly identifying the optimal dose and the number of subjects treated at the optimal dose, regardless of whether the data were generated from the correct or incorrect copula, even when there is substantial correlation between the two outcomes. Similar results were observed for a simple model that assumes independence, even in the presence of strong correlation. Further simulation results indicate that estimating the correlation parameter in copula models is difficult with the sample sizes used in Phase I-II clinical trials. CONCLUSIONS: Our simulation results indicate that the operating characteristics of phase I-II clinical trials are robust to misspecification of the copula model but that a simple model that assumes independence performs just as well due to difficulty in estimating the copula model correlation parameters from binary data. BioMed Central 2014-04-14 /pmc/articles/PMC4234400/ /pubmed/24731155 http://dx.doi.org/10.1186/1471-2288-14-51 Text en Copyright © 2014 Cunanan and Koopmeiners; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons PublicDomain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in thisarticle, unless otherwise stated.
spellingShingle Research Article
Cunanan, Kristen
Koopmeiners, Joseph S
Evaluating the performance of copula models in phase I-II clinical trials under model misspecification
title Evaluating the performance of copula models in phase I-II clinical trials under model misspecification
title_full Evaluating the performance of copula models in phase I-II clinical trials under model misspecification
title_fullStr Evaluating the performance of copula models in phase I-II clinical trials under model misspecification
title_full_unstemmed Evaluating the performance of copula models in phase I-II clinical trials under model misspecification
title_short Evaluating the performance of copula models in phase I-II clinical trials under model misspecification
title_sort evaluating the performance of copula models in phase i-ii clinical trials under model misspecification
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234400/
https://www.ncbi.nlm.nih.gov/pubmed/24731155
http://dx.doi.org/10.1186/1471-2288-14-51
work_keys_str_mv AT cunanankristen evaluatingtheperformanceofcopulamodelsinphaseiiiclinicaltrialsundermodelmisspecification
AT koopmeinersjosephs evaluatingtheperformanceofcopulamodelsinphaseiiiclinicaltrialsundermodelmisspecification